Cargando…

Comprehensive characterization of the epigenetic landscape in Multiple Myeloma

Background: Human multiple myeloma (MM) cell lines (HMCLs) have been widely used to understand the molecular processes that drive MM biology. Epigenetic modifications are involved in MM development, progression, and drug resistance. A comprehensive characterization of the epigenetic landscape of MM...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alaterre, Elina, Ovejero, Sara, Herviou, Laurie, de Boussac, Hugues, Papadopoulos, Giorgio, Kulis, Marta, Boireau, Stéphanie, Robert, Nicolas, Requirand, Guilhem, Bruyer, Angélique, Cartron, Guillaume, Vincent, Laure, Martinez, Anne Marie, Martin-Subero, José Ignacio, Cavalli, Giacomo, Moreaux, Jerome
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2022
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8825580/ https://www.ncbi.nlm.nih.gov/pubmed/35198065 http://dx.doi.org/10.7150/thno.54453

Ejemplares similares

EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma
por: Chemlal, Djamila, et al.
Publicado: (2023)

RNA-Sequencing-Based Transcriptomic Score with Prognostic and Theranostic Values in Multiple Myeloma
por: Alaterre, Elina, et al.
Publicado: (2021)

Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistance
por: Vikova, Veronika, et al.
Publicado: (2019)

PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs
por: Herviou, Laurie, et al.
Publicado: (2018)

DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells
por: Bruyer, Angelique, et al.
Publicado: (2018)

The BLM helicase is a new therapeutic target in multiple myeloma involved in replication stress survival and drug resistance
por: Ovejero, Sara, et al.
Publicado: (2022)

CD24, CD27, CD36 and CD302 gene expression for outcome prediction in patients with multiple myeloma
por: Alaterre, Elina, et al.
Publicado: (2017)

P843: METABOLOMIC CHARACTERIZATION OF HUMAN MULTIPLE MYELOMA CELL LINE TO STUDY TUMOR RESISTANCE TO DIFFERENT CLASSES OF THERAPEUTIC AGENTS
por: Steer, A., et al.
Publicado: (2022)

Kinome expression profiling to target new therapeutic avenues in multiple myeloma
por: de Boussac, Hugues, et al.
Publicado: (2020)

EZH2 in normal hematopoiesis and hematological malignancies
por: Herviou, Laurie, et al.
Publicado: (2015)

P844: CHARACTERIZATION OF MULTIPLE MYELOMA CELL LINES WITH ACQUIRED-RESISTANCE TO PROTEASOME INHIBITORS HIGHLIGHTS A LINK BETWEEN RESISTANCE AND METABOLIC DEREGULATION
por: De Boussac, H., et al.
Publicado: (2022)

Residual malignant and normal plasma cells shortly after high dose melphalan and stem cell transplantation. Highlight of a putative therapeutic window in Multiple Myeloma?
por: Caraux, Anouk, et al.
Publicado: (2012)

Targeting the methyltransferase SETD8 impairs tumor cell survival and overcomes drug resistance independently of p53 status in multiple myeloma
por: Herviou, Laurie, et al.
Publicado: (2021)

EZH2 is overexpressed in transitional preplasmablasts and is involved in human plasma cell differentiation
por: Herviou, Laurie, et al.
Publicado: (2019)

Multi-omics tumor profiling technologies to develop precision medicine in multiple myeloma
por: Ovejero, Sara, et al.
Publicado: (2021)

Var∣Decrypt: a novel and user-friendly tool to explore and prioritize variants in whole-exome sequencing data
por: Salma, Mohammad, et al.
Publicado: (2023)

miRNA profile at diagnosis predicts treatment outcome in patients with B-chronic lymphocytic leukemia: A FILO study
por: Duroux-Richard, Isabelle, et al.
Publicado: (2022)

RNA-sequencing data-driven dissection of human plasma cell differentiation reveals new potential transcription regulators
por: Kassambara, Alboukadel, et al.
Publicado: (2021)

Phenotypic Characterization of Diffuse Large B-Cell Lymphoma Cells and Prognostic Impact
por: Devin, Julie, et al.
Publicado: (2019)

Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors
por: Moreaux, J, et al.
Publicado: (2013)

Role of Polycomb Complexes in Normal and Malignant Plasma Cells
por: Varlet, Emmanuel, et al.
Publicado: (2020)

Drug metabolism and clearance system in tumor cells of patients with multiple myeloma
por: Hassen, Wafa, et al.
Publicado: (2014)

Antioxidant Defenses Confer Resistance to High Dose Melphalan in Multiple Myeloma Cells
por: Gourzones, Claire, et al.
Publicado: (2019)

Global miRNA expression analysis identifies novel key regulators of plasma cell differentiation and malignant plasma cell
por: Kassambara, Alboukadel, et al.
Publicado: (2017)

Inhibition of the Protein Arginine Methyltransferase PRMT5 in High-Risk Multiple Myeloma as a Novel Treatment Approach
por: Vlummens, Philip, et al.
Publicado: (2022)

Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study
por: Rossi, J-F, et al.
Publicado: (2009)

RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma
por: Viziteu, E, et al.
Publicado: (2017)

The Multiple Myeloma Landscape: Epigenetics and Non-Coding RNAs
por: Coira, Isabel F., et al.
Publicado: (2022)

SNaPshot as a Valuable Option for the Identification of Mutations in Myeloma
por: Moreaux, Jerome
Publicado: (2014)

Gene expression derived from alternative promoters improves prognostic stratification in multiple myeloma
por: Valcárcel, Luis V., et al.
Publicado: (2021)

An epigenetic regulator-related score (EpiScore) predicts survival in patients with diffuse large B cell lymphoma and identifies patients who may benefit from epigenetic therapy
por: Szablewski, Vanessa, et al.
Publicado: (2018)

Factors influencing extramedullary relapse after allogeneic transplantation for multiple myeloma
por: Vincent, L, et al.
Publicado: (2015)

Transcription/Replication Conflicts in Tumorigenesis and Their Potential Role as Novel Therapeutic Targets in Multiple Myeloma
por: Dutrieux, Laure, et al.
Publicado: (2021)

The hydroxymethylome of multiple myeloma identifies FAM72D as a 1q21 marker linked to proliferation
por: Chatonnet, Fabrice, et al.
Publicado: (2020)

DNA Repair Expression Profiling to Identify High-Risk Cytogenetically Normal Acute Myeloid Leukemia and Define New Therapeutic Targets
por: Gabellier, Ludovic, et al.
Publicado: (2020)

C-Reactive Protein Level: A Key Predictive Marker of Cachexia in Lymphoma and Myeloma Patients
por: Mallard, Joris, et al.
Publicado: (2019)

S189: PROTEOGENOMIC LANDSCAPE OF MULTIPLE MYELOMA
por: Ramberger, Evelyn, et al.
Publicado: (2023)

Treatment May Be Harmful: Mechanisms/Prediction/Prevention of Drug-Induced DNA Damage and Repair in Multiple Myeloma
por: Gourzones, Claire, et al.
Publicado: (2019)

The genetic landscape of 5T models for multiple myeloma
por: Maes, Ken, et al.
Publicado: (2018)

The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma
por: Choudhury, Samrat Roy, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_e816kpokspnfogl2cpv8oho7g0